Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 12/8/2020
SIETES contiene 93083 citas

 
 
 1 a 20 de 22 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita originalTiene citas relacionadas Cita con resumen
Moynihan R, MacDonald H, Bero L, Godlee F. Commercial influence and covid-19. BMJ 2020;369:24 de junio. [Ref.ID 103680]
2. Cita con resumen
Moynihan R, Albarqouni L, Nangla C, Dunn AG+, Lexchin J, Bero L. Financial ties between leaders of influential US professional medical associations and industry: cross sectional study. BMJ 2020;369:27 de mayo. [Ref.ID 103650]
3. Cita con resumen
Parker L, Fabbri A, Grundy Q, Mintzes B, Bero L. “Asset exchange”—interactions between patient groups and pharmaceutical industry: Australian qualitative study. BMJ 2019;367:12 de diciembre. [Ref.ID 103224]
4.Enlace a cita original Cita con resumen
Grundy Q, Bero L, Malone R. Interactions between non-physician clinicians and industry: a systematic review . PLOS Medicine 2013:26 de noviembre. [Ref.ID 96360]
5.Tiene citas relacionadas
Schroll JB, Bero L, Gotzsche PC. Searching for unpublished data for Cochrane reviews: cross sectional study. BMJ 2013;346:12. [Ref.ID 95960]
6. Cita con resumen
Bero L. Industry sponsorship and research outcome: a Cochrane review. JAMA Intern Med 2013;173:580-1. [Ref.ID 95262]
7.Tiene citas relacionadas Cita con resumen
Nguyen NY, Bero L. Medicaid drug selection committees and inadequate management of conflicts of interest. JAMA Intern Med 2013;173:338-43. [Ref.ID 95088]
8.Tiene citas relacionadas Cita con resumen
Hart B, Lundh A, Bero L. Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses. BMJ 2012;344:13. [Ref.ID 92177]
9.Tiene citas relacionadas Cita con resumen
Saint-Raymond A, Hill S, Martines J, Bahl R, Fontaine O, Bero L. CONSORT 2010. Lancet 2010;376:229-30. [Ref.ID 88917]
10.Tiene citas relacionadas Cita con resumen
Vedula SS, Bero L, Scherer RW, Dickersin K. Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med 2009;361:1963-71. [Ref.ID 87221]
11.Enlace a cita originalTiene citas relacionadas
12.Enlace a cita original Cita con resumen
13.Tiene citas relacionadas
Bero L. Relationship between pharmaceutical and tobacco companies. In reply. JAMA 2002;288:2973. [Ref.ID 64492]
14.
Shamasunder B, Bero L. Financial ties and conflicts of interested between pharmaceutical and tobacco companies. JAMA 2002;288:738-44. [Ref.ID 63024]
15.Tiene citas relacionadas Cita con resumen
Moynihan R, Bero L, Ross-Degnan D, Henry D, Lee K, Watkins J, Mah C, Soumerai SB. Coverage by the news media of the benefits and risks of medications. N Engl J Med 2000;342:1645-50. [Ref.ID 51089]
18.
de Vries TPGM, Henning RH, Hogerzeil HV, Bapna JS, Bero L, Kafle KK, Mabadeje AFB, Santoso B, Smith AJ. Impact of a short course in pharmacotherapy for undergraduate medical students: an international randomised controlled study. Lancet 1995;346:1454-7. [Ref.ID 25454]
19.
Barnes DE, Hanaver P, Slade J, Bero L, Glantz SA. Environment tobacco smoke. The Brown and Williamson documents. JAMA 1995;274:248-53. [Ref.ID 24563]
20.
Bero L, Barnes DE, Hanaver P, Slade J, Glantz SA. Lawyer control of the tobacco industry's external research program. The Brown and Williamson documents. JAMA 1995;274:241-7. [Ref.ID 24562]
Seleccionar todas
 
 1 a 20 de 22 siguiente >>